Nicolas Wlodarczyk is a medicinal chemist with expertise in organic synthesis and drug design. He has published 6 papers and presented at several conferences. His skills include heterocyclic synthesis, analytical techniques, and computer programs for cheminformatics and molecular modeling. He holds a PhD in organic and medicinal chemistry from Lille 2 University and has work experience in academia and industry drug discovery projects.

1.  5 Beechmount building, 34 old bakers court, BT6 8QY, Belfast
United Kingdom Nicolas
 0044 7 837 567 783
E-mail: Nicolas.wlod@gmail.com Wlodarczyk, PhD
Dynamic, open-minded, diligent
HIGHLIGHTS
 Strong knowledge and experience in synthetic organic and medicinal chemistry
 Design of small bioactive and lead optimization for pre-clinical candidate
 Supervisor of many internship students for 1 to 9 months
 Key contributor in interdisciplinary research projects
 6 publications in peer reviewed journal and numerous presentations (posters and seminars)
SKILLS
 Synthesis: Heterocyclic chemistry, multi-step synthesis, solid phase synthesis (parallel synthesis),
microwave synthesis, flow chemistry
 Analytical techniques: NMR, HPLC, GC, IR, UV, LC-MS, DLS
 Special skills: cheminformatic (Discovery Studio)
 Bibliographic seeking: Scifinder, Reaxys, RSS feed
 Computer skills: Word, Excel, Power Point, ISIS Draw, Chemdraw, ISIS Base, Photoshop, E-
notebook, Chembridge molecular library
 Languages: English (expert), French (native)
EDUCATION
PhD in Synthetic organic and medicinal chemistry with an excellent mention 2008
Lille 2 University - France
MD in Drug Design with an excellent mention 2005
Lille 2 University - France
BSc in Pharmaceutical sciences with an excellent mention 2003
Lille 2 University – France
Diploma of technician 2002
Lille 1 University – France
French baccalaureate specialized in chemistry with an excellent mention 2000
Valentine Labbé High school, La Madeleine - France
EXPERIENCES
Medicinal Chemist (from February 2012)
 ALMAC Discovery (Research and Development department), Craigavon, Northern Ireland
 Subjects: Different confidential patented subjects which change in function of the results and the
deadlines
 Hit finding: resynthesis and study of the stability (LCMS and NMR) to validate the hits, then establish
some SAR to prepare some series which are chosen in function of the patentability and the
preliminary biological results

2.  Lead optimization: chemical modification of potent compounds to improve ADME parameter
(solubility, stability, pharmacokinetic, toxicity), to select any of those to preclinical studies
Temporary research associate (September 2011 to October 2009)
 Laboratory of Medicinal Chemistry, URA(CNRS)2128, Institut Pasteur, Paris, France
 Supervisor: Y.L. Janin, PhD
 Research subject: Design, synthesis of parasitic serine protease inhibitors (confidential)
 Optimization of the synthesis of the chemical scaffolds (quinoline) to prepare chemical libraries
 Interdisciplinary exchange between chemistry, biology (in vitro and in vivo activity), biophysic (STD-
NMR, X-Ray crystallography) and bioinformatic (docking and QSAR)
 Measurement of small molecules aggregation by Dynamic Light Scattering (DLS)
 Results: 1 publication (other publications and patents are in preparation), 200 compounds prepared
on different series, detection of nuisance compounds
Temporary lecturer (August 2009 to October 2008)
 Laboratory of Pharmacological and Toxicological Chemistry and Biochemistry, UMR(CNRS)8601,
Paris Descartes University, France
 Supervisor: Y. Le Merrer, Pr., team leader
 Courses teaching: organic and inorganic chemistry in license degree
 Research subject: Design, synthesis and biological evaluation of methionine aminopeptidase
inhibitors in cancer treatment
PhD internship (September 2008 to September 2005)
 Faculty of Pharmacy, Lille II University, France
 Supervisor: J-P. Hénichart, Pr., team leader
 Research subject: Design, synthesis and pharmacological evaluation of farnesyltransferase
inhibitors in cancer treatment
 Heterocyclic chemistry (1,4-diazepane and 4-aminopiperidine) and Parallel synthesis on solid phase
 Assay by myself of my inhibitors by enzymatic assay (fluorescence method)
 Rationalization of in vitro and in vivo results from docking studies and physical parameters
 Results: 5 publications, structure-activity relationships to design a promising pharmcophore, good in
vitro and in vivo inhibitors
Internship as technician (July 2005 to October 2002)
 Faculty of Pharmacy, Lille II University, France
 Supervisor: J-P. Hénichart, Pr., team leader
 Acquired essential laboratory skills by: synthesizing heterocyclic compounds, purifying by usual
techniques as extraction, recrystallization, flash chromatography and analyzing by chromatography
(TLC, HPLC, LCMS) and spectroscopic methods (IR, NMR and MS)
 Supervised many students during their trainee period (1 week to 9 months)
 Synthesis of heterocyclic compounds for Genfit (CRO, LOOS, France), patent WO2008/012470
PUBLICATIONS
1. On the Knorr synthesis of 6-bromo-4-methylquinolin-2(1H)-one. Wlodarczyk N., Simenel C.,
Delepierre M., Barale J-C. Janin Y. L. Synthesis, 2011, 6, 934-942

3. 2. Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule
agents in hormone-resistant prostate cancer. Wlodarczyk N., Ryckewaert D., Gilleron P., Lemoine
A., Farce A., Chavatte P., Dubois J., Pommery N., J-P. Hénichart, Millet R. J. Med. Chem., 2011, 54,
1178-1190
3. Design, synthesis and biological evaluation of substituted dioxodibenzothiazepines and
dibenzocycloheptanes as farnesyltransferase inhibitors. Gilleron P., Wlodarczyk N., Houssin R.,
Farce A., Laconde G., Goossens J-F., Lemoine A., Pommery N., Hénichart J-P., Millet R. Bioorg.
Med. Chem. Lett., 2007, 17, 5465-5471
4. Synthesis of 1,4-diazepin-5-ones under microwave irradiation and their reduction products
Wlodarczyk N., Gilleron P., Millet R., Houssin R., Hénichart J.-P. Tetrahedron Lett., 2007, 48, 2583-
2586
5. Solid-phase synthesis and pharmacological evaluation of a library of peptidomimetics as potential
farnesyltransferase inhibitors: an approach to new lead compounds. Gilleron P., Millet R., Houssin R.,
Wlodarczyk N., Farce A., Lemoine A., Goossens J-F., Chavatte P., Pommery N., Henichart J-P. Eur.
J. Med. Chem., 2006, 41,745-55
6. In vitro and in vivo evaluation of two rational-designed nonpeptidic farnesyltransferase inhibitors on
HT29 human colon cancer cell lines. Wlodarczyk N., Gilleron P., Millet R., Houssin R., Goossens J.-
F., Lemoine A., Pommery N., Wei M. X., Hénichart J.-P. Oncol. Res., 2005, 16, 107-118
PUBLISHED ABSTRACTS AND CONFERENCE PRESENTATIONS
(only the most important)
Design, synthesis of novel farnesyltransferase inhibitors as novel microtubule-destabilizing agents in PC3
cells. N. Wlodarczyk, D. Ryckewaert, P. Gilleron, A. Lemoine, A Farce, C. Furman, J. Dubois, P.
Chavatte, J-P. Henichart, R. Millet. 21st International Symposium of Medicinal Chemistry, Brussel
(Belgium), September 5-9 2010
Design, synthesis and pharmacological evaluation of potent farnesyltransferase inhibitors with the 1,4-
diazepane scaffold. N. Wlodarczyk, P. Gilleron, P. Six, A. Lemoine, A Farce, R. Houssin, P. Chavatte, J.
st
Dubois, J-P. Henichart, R. Millet. 44 International Meeting of Therapeutic Chemistry, Angers (France),
Jully 1-4 2008
Award for the Vocation in Therapeutic Chemistry (from Servier)
Design, synthesis and pharmacological evaluation of potent farnesyltransferase inhibitors with 7-phenyl-
1,4-diazepane scaffold. Wlodarczyk N., Gilleron P., Lemoine A., Dubois J., Pommery N., Houssin R.,
th
Hénichart J-P., Millet R. 15 Young Researchers Day of the French Society of Therapeutic Chemistry
st
(France), Paris, January 31 2008